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Case Presentation:
A Case Report of an Aggressive Mantle Cell Lymphoma Masquerading as a 
Chronic Lymphocytic Leukemia With Catastrophic Treatment Complications
Discussion:
MCL is an aggressive non-Hodgkins lymphoma with poorer prognosis of all other lymphomas. Though not curable 
outside of transplant, frequent remissions (60%-90%) can be obtained albeit short lasting (1-2 years).1 MCL is 
often misdiagnosed as CLL. Flow cytometric immunophenotyping often helps differentiate CLL from MCL, and 
a characteristic CLL phenotype is considered essentially diagnostic.2 There is significantly higher expression 
of CD23 in CLL. MCL typically is negative for CD23, but 25 % cases can be dim positive.3,4 CLL on the other 
hand can occasionally be CD23 negative. Thus NHL often can be less obvious and confounds the diagnosis if a 
leukemic phase occurs at presentation. MCL is more specifically identified by the presence of the translocation 
t(11;14)(q13;q32), but cyclin D1-negative variants do exist. FISH assay is by far the most sensitive and specific 
technique for t(11:14) identification.5 This should be considered in newly diagnosed CLL patients with atypical 
features especially B grade symptoms at initial presentation, massive splenomegaly, immunopenotypic feature 
showing moderate bright CD20 and bright surface light chain expression. Given the importance of stem cell 
transplants for MCL patients, it is important to recognize this, as fludarabine therapy can impair successful 
collection of stem cells.6 Bone marrow biopsy though not required for diagnosis for CLL, but should be considered 
in atypical presentations, discordance in the immunophenotypic markers, presence of cytopenias and preferably 
prior to treatment initiation.
Rituximab induced CRS or splenic rupture is very rarely reported in literature. There is emerging evidence which 
implicates IL-6 as a central mediator in CRS. Toclilizumab (IL-6 blocker) is used as first line immunosuppressive 
therapy in clinical trials.7 Ophthalmic side effect of rituximab is reported including transient ocular edema, 
transient visual changes and severe loss of visual acuity; however these are very rare. The risk of reaction may 
correlate with the aggressiveness and burden of the disease. Hence we should consider aggressive hydration, 
pre-treatment with steroids, antihistamines and holding or dose reduction of rituximab with first cycle. Post-
marketing surveillance database on rituximab indicates a mortality of 0.04–0.07% associated with the drug, 
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Mantle cell Lymphoma (MCL) and chronic lymphocytic leukemia (CLL) account for majority of Small B-cell 
neoplasms (SBCNs) that express CD5 without CD10. We present a patient case with aggressive MCL presenting 
with leukocytosis and splenomegaly mimicking CLL initially on immunophenotypic features.
A 55-year-old presented with abdominal pain, drenching night sweats, early satiety, anorexia and significant 
weight loss for 8-month duration. On exam she had generalized lymphadenopathy and massive splenomegaly.  
Complete blood cell count showed pancytopenia with normal blood chemistry and LDH 778 U/L (Table1). 
Differential count showed predominant lymphocytosis. Peripheral smear 
showed increased lymphocytes, condensed nuclear chromatin, smudge 
cells and occasional left shifted neutrophils. CT imaging showed diffuse 
lymphadenopathy and splenomegaly measuring 24 x 17 cm (Figure 1). Flow 
cytometry showed a large monoclonal B-cell population kappa light chain 
restriction, dim CD19, CD20, CD5, and variable expression of CD23. This 
population demonstrated moderate to bright CD38 and negative for CD10 
and CD11c (Figure 2). The findings were most compatible with a diagnosis of 
chronic lymphocytic leukemia. FISH panel was pending at this point. 
Due to B-symptoms and ongoing pain, decision was made to initiate FCR 
chemotherapy (Fludarabine, Cyclophosphamide, Rituximab). A bone marrow 
was done and rituximab treatment was initiated a day later. Thirty minutes 
post-initiation of Rituximab, patient developed rigors, chills and nausea. 
She became hypotensive, hypoglycemic and developed respiratory failure 
requiring intubation and vasopressor support. Her clinical features and work 
up (Table 1) were consistent with Cytokine Release Syndrome (CRS) and she 
was started on steroids. 
She was treated with antibiotics, aggressive fluid resuscitation, bicarbonate infusion and emergently initiated 
on hemodialysis. Echocardiogram showed dilated right ventricle with decreased Ejection fraction and CT scan 
showed findings concerning for splenic infarction.
By this time the peripheral blood FISH panel resulted with t(11;14) consistent with MCL. Bone marrow biopsy 
resulted as very aggressive MCL with associated TP53 deletion and Ki-67 proliferation index 60% (Figure 3). 
Though her clinical status improved, she developed decreased vision in both eyes. On day 30, she developed 
intractable abdominal pain and severe thrombocytopenia. Urgent CT scan demonstrated splenic rupture and 
hemoperitoneum (Figure 4). She was made comfort care and died shortly after.
Table 1
Labs At Presentation
4 Hours Post 
Rituximab
Hemoglobin 9.4 g/ dL 6.2 g/ dL
WBC 44, 000 / μL 24, 000 / μL
Platelet Count 106,000 / μL 74,000 / μL
Serum Potassium 4.4 mEq/L 7.1 mEq/L
Serum Uric Acid 2.2 mg/L 6.8 mg/L
LDH 777 U/L 8750 U/L
Lactate - >30 mmol/L
PT 1.1 2.8
PTT 14 28.8
D-Dimer - 12.2 µg/mL
Fibrinogen - 296 mg/dL
Haptoglobin - <7mg/dL
AST 44 U/L 1326 U/L
ALT 38 U/L 200 U/L
T. bilirubin 1.2 mg/dL 8.2 mg/dL
Serum Cortisol - 122 μg/dL
  
Figure 1: CT scan 
image showing massive 
splenomegaly. Figure 4: CT scan image 
showing splenic rupture.
Figure 2: Flow cytometry showing a 
large monoclonal B-cell population Kappa 
light chain restriction, dim CD19, CD20, 
CD5, and variable expression of CD23.
Figure 3B: Bone marrow aspirate (100x magnification) 
showing large lymphoid cells with slightly folded nuclei and 
vasicular chromatin.
Figure 3A: Bone marrow core biopsy (40x magnification) 
(insert in white box 100x magnification) showing sheets 
of large transformed lymphocytes with occasional nucleoli 
prominent nucleoli. 
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